<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04922398</url>
  </required_header>
  <id_info>
    <org_study_id>Hawaa-9</org_study_id>
    <nct_id>NCT04922398</nct_id>
  </id_info>
  <brief_title>Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency</brief_title>
  <official_title>Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed Saad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hawaa Fertility Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      60 cases with premature ovarian insufficiency will be randomized to either receive PRP or&#xD;
      saline injection in their ovaries. Then follow up by hormonal &amp; ultrasound &amp; clinically to&#xD;
      monitor any changes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this pilot study, 60 patients will be included. All patients will have a premature ovarian&#xD;
      insufficiency (PORs) who meet at least two of the following three Bologna criteria.&#xD;
&#xD;
      The following data will be registered for all the cases: age, weight, height, menstrual&#xD;
      history, previous pregnancies and their outcome, no. of living children and age of the&#xD;
      youngest, history symptoms, married for how long, infertility duration and whether primary or&#xD;
      secondary. Estimation of Antral Follicle Count (AFC) will be done for all the patients by&#xD;
      transvaginal ultrasound (TVUS). Finally, a blood sample will be withdrawn for the following&#xD;
      lab. Investigations: FSH, LH, E2, AMH, TSH, Prolactin before inclusion of the patients in the&#xD;
      study.&#xD;
&#xD;
      A written consent form will be signed by all patients after complete explanation of the&#xD;
      procedures and the expectations of the trial. Patients will be randomized into 2 groups (A&amp;&#xD;
      B). All will undergo a transvaginal intervention through an ovum pickup needle 17 G for the&#xD;
      procedure. The group A consists of 30 patients, who will receive a PRP (autologous&#xD;
      platelet-rich plasma injection) with activation with calcium chloride. The group B consists&#xD;
      of 30 patients, who will receive a normal saline inj. 0.9% Nacl.&#xD;
&#xD;
      Sample preparation of the PRP:&#xD;
&#xD;
      According to the classification proposed by Ehrenfest, 4 different types of PRP are defined,&#xD;
      depending on the content of cells and the presence of fibrin. In regards to the&#xD;
      Classification of PRP in this case study, it is used as a commercial type of PRP with the&#xD;
      lower concentration (2.5 x 3 times) system, Ycellbio PRP. The process will be carried out&#xD;
      under strict aseptic conditions as well as optimum temperature regulations, i.e., 21-24°C.&#xD;
      PRP will be prepared according to the manufacturer's guidelines. Draw 1 CC anticoagulant&#xD;
      (sodium citrate) into a 20 CC syringe. Coat the inside walls of the syringe with the drawn&#xD;
      anticoagulant. Then draw 14 CC blood under complete aseptic condition into a 20 CC syringe.&#xD;
      Swing the syringe slowly to mix blood and anticoagulant well. Inject the blood slowly into&#xD;
      the Ycellbio tube. Straighten the tube when the blood reaches the Y-funnel. Inject the blood&#xD;
      into the Ycellbiotube to the appropriate level as indicated by the lines. Close the Ycellbio&#xD;
      tube with silicon stopper using a forceps. Centrifuge at 3500 RPM at time 5 min. After the 5&#xD;
      min. spin, the Buffy coat is well visible. Twist the controller to adjust the height of buffy&#xD;
      coat to the marked line. Twist the controller to adjust the height of buffy coat to the&#xD;
      marked line. Prepare a 18 G ½ needle and a 3 CC syringe for PRP harvest. Open the silicone&#xD;
      stopper using an alcohol soaked cotton. Extract 2.0 CC PRP while slowly swirling the needle&#xD;
      in the area of the PRP into a 3 CC syringe. The same process is done for another 3 blood&#xD;
      samples to have a total of 8 ml PRP to be used for both ovaries.&#xD;
&#xD;
      In the last step, the volume immediately above the erythrocyte layer will be collected.&#xD;
      Calcium gluconate in conc. 1:9 will be used as an activator. After activation, in a period&#xD;
      less than 2 min, approximately 4 ml of the PRP will be injected into each ovary by TVUS.&#xD;
&#xD;
      Monitoring &amp; follow up:&#xD;
&#xD;
      The changes in the hormones at day 3 of the menstrual cycle: FSH, LH, estradiol, AMH will be&#xD;
      closely monitored,after the application of the procedure in each group after 3 months. The&#xD;
      investigators will also monitor the number of antral follicles &amp; changes in the menstrual&#xD;
      cycles &amp; spontaneous ovulation before and after 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 20, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>60 patients with premature ovarian failure will be divided into 2 groups. The group A consists of 30 patients, who will receive a PRP (autologous platelet-rich plasma injection) with activation with calcium chloride. The group B consists of 30 patients, who will receive a normal saline inj. 0.9% Nacl.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FSH hormonal changes</measure>
    <time_frame>3rd day of the 3rd menstrual cycle after the procedure</time_frame>
    <description>The changes in the hormones at day 3 of the menstrual cycle: FSH monitored</description>
  </primary_outcome>
  <primary_outcome>
    <measure>vaginal ultrasound monitoring of the ovaries</measure>
    <time_frame>3rd day of the 3rd menstrual cycle after the procedure</time_frame>
    <description>monitor the number of antral follicles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical follow up</measure>
    <time_frame>3rd day of the 3rd menstrual cycle after the procedure</time_frame>
    <description>changes in the menstrual cycle by history taking &amp; questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LH hormonal changes</measure>
    <time_frame>3rd day of the 3rd menstrual cycle after the procedure</time_frame>
    <description>serum LH at day 3 of the menstrual cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>E2 hormonal changes</measure>
    <time_frame>3rd day of the 3rd menstrual cycle after the procedure</time_frame>
    <description>serum E2 at day 3 of the menstrual cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AMH hormonal changes</measure>
    <time_frame>3rd day of the 3rd menstrual cycle after the procedure</time_frame>
    <description>serum AMH</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Premature Ovarian Failure</condition>
  <arm_group>
    <arm_group_label>Group A: PRP group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preparation of PRP sample fro the patient own blood then the volume immediately above the erythrocyte layer was collected. Calcium gluconate in conc. 1:9 will be used as an activator. After activation, in a period less than 2 min, approximately 4 ml of the PRP will be injected into each ovary by TVUS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: saline group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>consists of 30 patients, who will receive 4 ml of a normal saline inj. 0.9% Nacl. then injected into each ovary by TVUS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>platelet rich plasma</intervention_name>
    <description>blood will be withdrawn from the patient then separation of the platelet rich layer and then injection in the ovary</description>
    <arm_group_label>Group A: PRP group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>0.9% normal saline will be injected in each ovary</description>
    <arm_group_label>Group B: saline group</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PORs who meet at least two of the following three Bologna criteria&#xD;
&#xD;
          -  AMH: 0.1-1 ng/ml.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ovarian insufficiency due to gonadal dysgenesis and -&#xD;
&#xD;
          -  chromosomal abnormalities,&#xD;
&#xD;
          -  immunoglobulin A deficiency,&#xD;
&#xD;
          -  the use of anticoagulants,&#xD;
&#xD;
          -  psychotropic medicaments,&#xD;
&#xD;
          -  psychiatric disorders,&#xD;
&#xD;
          -  carcinomas or&#xD;
&#xD;
          -  a history of chronic pelvic pain.&#xD;
&#xD;
          -  Women with present infection,&#xD;
&#xD;
          -  haemoglobin lower than 11 g/L or&#xD;
&#xD;
          -  platelets lower than 150 x 10ʒ/μL were excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>only in female patients</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed F Elsherbiny, phd.MD</last_name>
    <role>Study Director</role>
    <affiliation>Professor of OB &amp; GYN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed S Saad, phd, MD</last_name>
    <phone>01221709989</phone>
    <email>drahmedsaad@live.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed F Elsherbiny, phd.MD</last_name>
    <phone>01094070920</phone>
    <email>mohfarag171@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Benha University</name>
      <address>
        <city>Banhā</city>
        <state>Qalyubiya</state>
        <zip>13512</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>June 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>June 5, 2021</last_update_submitted>
  <last_update_submitted_qc>June 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Ahmed Saad</investigator_full_name>
    <investigator_title>Assistant professor of obstetrics &amp; gynecology</investigator_title>
  </responsible_party>
  <keyword>premature ovarian failure</keyword>
  <keyword>poor responders</keyword>
  <keyword>poor ovarian reserve</keyword>
  <keyword>PRP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>the protocol the excel sheet</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>6 months</ipd_time_frame>
    <ipd_access_criteria>6 months</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

